Brief: Sinopharm Says China National Accord Medicines H1 Net Profit Attributable RMB 606.2 Million
BRIEF-Sinopharm Says China National Accord Medicines H1 Net Profit Attributable RMB 606.2 Million Aug 17 (Reuters) - China National Accord Medicines Corp Ltd 000028.SZ:
CHINA NATIONAL ACCORD MEDICINES H1 2026 NET PROFIT ATTRIBUTABLE RMB606.2 MILLION, DOWN 8.97% Y/Y
CHINA NATIONAL ACCORD MEDICINES H1 2026 REVENUE RMB36.27 BILLION
Further company coverage: 000028.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For